The abstract is read at the publisher; the summary is JClub's.
In the FINE-HEART pooled analysis of 18 991 advanced cardiovascular-kidney-metabolic participants, women had higher multimorbidity and lower all-cause mortality risk (adjusted HR 0.83).
- Why it matters: Sex differences in CKM syndrome burden and care are incompletely characterized, including whether outcomes and finerenone benefits differ between women and men.
- What they did: Individual participant data were pooled from FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF, comparing men vs women with adjusted Cox models for first HF hospitalization, cardiovascular death, major adverse cardiovascular events, kidney outcomes, and all-cause death.
- The result: Over a median 2.9-year follow-up, HF hospitalization or cardiovascular death rates were similar (4.8 vs 3.9 per 100 patient-years; adjusted HR 0.97, 95% CI 0.89-1.06, P = .52), while finerenone benefits were consistent across sexes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.